ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "NPS Pharmaceuticals, Inc." (NPSP) Report Updated: Nov 24, 2014 | Print This Page

Get more stock ratings by Louis Navellier

"NPS Pharmaceuticals, Inc." (NPSP)

Rating: Buy Volatility: Moderate
Total Grade: B Industry: Biotechnology
Competitors: ENTA, AGIO, MACK, MDXG

Stock Analysis

Rating: Monthly View

A
B
C
D
F
November December January February March April May June July August September October

Rating: Weekly View

This Week: B down upgrade
Last Week: C same no change
Two Weeks Ago: C up no change
service keys

"NPS Pharmaceuticals, Inc."© quotemedia

Company Profile

NPS Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic products for gastrointestinal and endocrine disorders, and various medical needs. The company’s primary clinical programs include two therapeutic peptides to restore or replace biological functions comprising GATTEX, a Phase 3 clinical trial product for short bowel syndrome; and Natpara, a recombinant human parathyroid hormone 1-84, which is in Phase 3 clinical development trials. It also develops NPSP790 and NPSP795 calcilytic compounds that are in Phase I trials for the treatment of rare endocrine disorders. The company has collaborative and license agreements with Amgen Inc., Janssen, GlaxoSmithKline, Kyowa Hakko Kirin, and Nycomed Danmark ApS. NPS Pharmaceuticals, Inc. was founded in 1986 and is based in Bedminster, New Jersey.

Recent News: "NPS Pharmaceuticals, Inc."